Advisory Cmte. Conflict-Of-Interest Waiver Details Should Be Public – Bristol
Executive Summary
FDA advisory committee members granted conflict-of-interest waivers should be required to disclose the companies to which they have financial ties, Bristol-Myers Squibb said in comments to FDA
You may also be interested in...
Advisory Panelist Conflicts Of Interest Have Weak Favorable Effect On Votes
FDA advisory committee members with conflicts of interest are more likely to vote favorably for the drug being discussed than those without conflicts, a study conducted by Public Citizen's Health Research Group found
Advisory Panelist Conflicts Of Interest Have Weak Favorable Effect On Votes
FDA advisory committee members with conflicts of interest are more likely to vote favorably for the drug being discussed than those without conflicts, a study conducted by Public Citizen's Health Research Group found
New FDA Conflict Of Interest Policy Enacted At MT 100 Committee Meeting
FDA's new conflict-of-interest disclosure policy for advisory committee members was inaugurated at the Aug. 4 Peripheral & Central Nervous System Drugs Advisory Committee meeting